Comment on ‘Oncogenic alterations in <i>KIR3DL1</i> in cutaneous acral CD8+ lymphoproliferative disorder’ by Wobser <i>et al</i>.

Identifying pathognomonic features that differentiate primary cutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) from other CD8+ aggressive lymphomas is a major concern. Doing so can facilitate diagnosis and allow clinicians to optimize clinical management. In this context, we read with great interest the article from Wobser et al., which proposed a molecular characterization of five cutaneous acral CD8+ TLPDs and identified KIR3DL1 alterations in addition to PIK3R1 alterations. To broaden this spectrum, we propose genomic profiling of six cutaneous acral CD8+ TLPDs from our database and identify alterations related to oncogenic pathways such as the AKT pathway and the Janus kinase–signal transducer and activator of transcription protein pathway. We also confirm the decreased mRNA expression of KIR3DL1 in this setting.